N/A
Completed N=8
Bosentan and Pulmonary Endothelial Function
Source: ClinicalTrials.gov NCT01721564 ↗Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Feb 2013
Primary outcomePrimary: Acetylcholine Vascular Reactivity Response — 180 percentage of baseline
Summary
6 months therapy of Bosentan, an endothelin antagonist, will lead to improvement in pulmonary microvascular endothelial function.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Acetylcholine Vascular Reactivity Response |
180 | — |
| SECONDARY Intravascular Ultrasound - Pulmonary Artery Wall Thickness |
34 | — |
Eligibility Criteria
Inclusion Criteria
- Pulmonary arterial hypertension; idiopathic and connective tissue disease associated
- Confirmed or invasive haemodynamic:
- Mean pulmonary arterial pressure greater than or equal to 25 millimeters of mercury
- Pulmonary capillary wedge pressure less than 15 millimeters of mercury
- No prior pulmonary hypertension specific therapy
- Ability to provide informed consent
Exclusion Criteria
- Contra-indications to medications used to test endothelial function; acetylcholine, sodium nitroprusside, NG-Monomethyl-L-Arginine, L-arginine
- Advanced renal disease
- Previous allergic reaction to contrast agents
Data sourced from ClinicalTrials.gov (NCT01721564). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.